By Helgi Library - July 9, 2025
EC Pharmacies made a net profit of EUR -0.755 mil in 2024, up 0% compared to the previous year. Total sales reached EUR 3.71 mil, ...
By Helgi Library - July 14, 2025
EC Pharmacies stock traded at EUR 14.4 per share at the end 2024 translating into a market capitalization of USD 15.9 mil. Since ...
By Helgi Library - July 9, 2025
EC Pharmacies made a net profit of EUR -0.755 mil with revenues of EUR 3.71 mil in 2024, up by 0% and up by 0%, respectively...
| Profit Statement | 2022 | 2023 | 2024 | |
| Sales | EUR mil | ... | ... | 3.71 |
| Gross Profit | EUR mil | ... | ... | 0.521 |
| EBITDA | EUR mil | ... | ... | -0.755 |
| EBIT | EUR mil | ... | ... | -0.755 |
| Financing Cost | EUR mil | ... | ... | 0 |
| Pre-Tax Profit | EUR mil | ... | ... | -0.755 |
| Net Profit | EUR mil | ... | ... | -0.755 |
| Dividends | EUR mil | ... | ... | 0 |
| Balance Sheet | 2022 | 2023 | 2024 | |
| Total Assets | EUR mil | ... | 1.73 | 3.89 |
| Non-Current Assets | EUR mil | ... | 0.915 | 3.22 |
| Current Assets | EUR mil | ... | 1.63 | 0.677 |
| Working Capital | EUR mil | ... | 1.24 | 0.150 |
| Shareholders' Equity | EUR mil | ... | 1.73 | 3.89 |
| Liabilities | EUR mil | ... | 0 | 0 |
| Total Debt | EUR mil | ... | 0 | 0 |
| Net Debt | EUR mil | ... | -0.454 | -0.477 |
| Ratios | 2022 | 2023 | 2024 | |
| ROE | % | ... | ... | -26.9 |
| ROCE | % | ... | ... | -27.3 |
| Gross Margin | % | ... | ... | 14.0 |
| EBITDA Margin | % | ... | ... | -20.4 |
| EBIT Margin | % | ... | ... | -20.4 |
| Net Margin | % | ... | ... | -20.4 |
| Net Debt/EBITDA | ... | ... | 0.632 | |
| Net Debt/Equity | % | ... | -26.3 | -12.3 |
| Valuation | 2022 | 2023 | 2024 | |
| Market Capitalisation | USD mil | 15.3 | 15.9 | 15.9 |
| Enterprise Value (EV) | USD mil | ... | 15.4 | 15.4 |
| Number Of Shares | mil | 1.00 | 1.00 | 1.00 |
| Share Price | EUR | 14.4 | 14.4 | 14.4 |
| EV/EBITDA | ... | ... | -18.8 | |
| EV/Sales | ... | ... | 3.82 | |
| Price/Earnings (P/E) | ... | ... | -19.1 | |
| Price/Book Value (P/BV) | ... | 8.34 | 3.70 | |
| Dividend Yield | % | ... | ... | 0 |
Get all company financials in excel:
| overview | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
| income statement | |||||||||||||
| Sales | EUR mil | ... | ... | ... | ... | ||||||||
| Gross Profit | EUR mil | ... | ... | ... | ... | ||||||||
| EBIT | EUR mil | ... | ... | ... | ... | ||||||||
| Net Profit | EUR mil | ... | ... | ... | ... | ||||||||
| ROE | % | ... | ... | ... | ... | ||||||||
| EBIT Margin | % | ... | ... | ... | ... | ||||||||
| Net Margin | % | ... | ... | ... | ... | ||||||||
| balance sheet | |||||||||||||
| Total Assets | EUR mil | ... | ... | ... | |||||||||
| Non-Current Assets | EUR mil | ... | ... | ... | |||||||||
| Current Assets | EUR mil | ... | ... | ... | |||||||||
| Shareholders' Equity | EUR mil | ... | ... | ... | |||||||||
| Liabilities | EUR mil | ... | ... | ... | |||||||||
| Non-Current Liabilities | EUR mil | ... | ... | ... | |||||||||
| Current Liabilities | EUR mil | ... | ... | ... | |||||||||
| Net Debt/EBITDA | ... | ... | ... | ... | |||||||||
| Net Debt/Equity | % | ... | ... | ... | |||||||||
| Cost of Financing | % | ... | ... | ... | ... | ... | |||||||
| cash flow | |||||||||||||
| Total Cash From Operations | EUR mil | ... | ... | ... | ... | ... | |||||||
| Total Cash From Investing | EUR mil | ... | ... | ... | ... | ... | |||||||
| Total Cash From Financing | EUR mil | ... | ... | ... | ... | ... | |||||||
| Net Change In Cash | EUR mil | ... | ... | ... | ... | ||||||||
| valuation | |||||||||||||
| Market Capitalisation | USD mil | 17.7 | 16.3 | 15.3 | |||||||||
| Enterprise Value (EV) | USD mil | ... | ... | ... | |||||||||
| Number Of Shares | mil | 1.00 | 1.00 | 1.00 | |||||||||
| Share Price | EUR | 14.4 | 14.4 | 14.4 | |||||||||
| Price/Earnings (P/E) | ... | ... | ... | ... | |||||||||
| Price/Cash Earnings (P/CE) | ... | ... | ... | ... | |||||||||
| EV/EBITDA | ... | ... | ... | ... | |||||||||
| Price/Book Value (P/BV) | ... | ... | ... | ||||||||||
| Dividend Yield | % | ... | ... | ... | ... |
| income statement | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
| income statement | |||||||||||||
| Sales | EUR mil | ... | ... | ... | ... | ||||||||
| Cost of Goods & Services | EUR mil | ... | ... | ... | ... | ||||||||
| Gross Profit | EUR mil | ... | ... | ... | ... | ||||||||
| Staff Cost | EUR mil | ... | ... | ... | ... | ||||||||
| EBITDA | EUR mil | ... | ... | ... | ... | ||||||||
| Depreciation | EUR mil | ... | ... | ... | ... | ||||||||
| EBIT | EUR mil | ... | ... | ... | ... | ||||||||
| Net Financing Cost | EUR mil | ... | ... | ... | ... | ||||||||
| Financing Cost | EUR mil | ... | ... | ... | ... | ||||||||
| Financing Income | EUR mil | ... | ... | ... | ... | ||||||||
| Extraordinary Cost | EUR mil | ... | ... | ... | ... | ||||||||
| Pre-Tax Profit | EUR mil | ... | ... | ... | ... | ||||||||
| Tax | EUR mil | ... | ... | ... | ... | ||||||||
| Minorities | EUR mil | ... | ... | ... | ... | ||||||||
| Net Profit | EUR mil | ... | ... | ... | ... | ||||||||
| Net Profit Avail. to Common | EUR mil | ... | ... | ... | ... | ||||||||
| Dividends | EUR mil | ... | ... | ... | ... | ||||||||
| growth rates | |||||||||||||
| Total Revenue Growth | % | ... | ... | ... | ... | ... | |||||||
| Operating Cost Growth | % | ... | ... | ... | ... | ... | |||||||
| Staff Cost Growth | % | ... | ... | ... | ... | ... | ... | ||||||
| EBITDA Growth | % | ... | ... | ... | ... | ... | |||||||
| EBIT Growth | % | ... | ... | ... | ... | ... | |||||||
| Pre-Tax Profit Growth | % | ... | ... | ... | ... | ... | |||||||
| Net Profit Growth | % | ... | ... | ... | ... | ... | |||||||
| ratios | |||||||||||||
| ROE | % | ... | ... | ... | ... | ||||||||
| ROA | % | ... | ... | ... | ... | ||||||||
| ROCE | % | ... | ... | ... | ... | ||||||||
| Gross Margin | % | ... | ... | ... | ... | ||||||||
| EBITDA Margin | % | ... | ... | ... | ... | ||||||||
| EBIT Margin | % | ... | ... | ... | ... | ||||||||
| Net Margin | % | ... | ... | ... | ... | ||||||||
| Payout Ratio | % | ... | ... | ... | ... | ||||||||
| Cost of Financing | % | ... | ... | ... | ... | ... | |||||||
| Net Debt/EBITDA | ... | ... | ... | ... |
| balance sheet | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
| balance sheet | |||||||||||||
| Cash & Cash Equivalents | EUR mil | ... | ... | ... | |||||||||
| Receivables | EUR mil | ... | ... | ... | |||||||||
| Inventories | EUR mil | ... | ... | ... | |||||||||
| Other ST Assets | EUR mil | ... | ... | ... | |||||||||
| Current Assets | EUR mil | ... | ... | ... | |||||||||
| Property, Plant & Equipment | EUR mil | ... | ... | ... | |||||||||
| LT Investments & Receivables | EUR mil | ... | ... | ... | |||||||||
| Intangible Assets | EUR mil | ... | ... | ... | ... | ... | |||||||
| Goodwill | EUR mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| Non-Current Assets | EUR mil | ... | ... | ... | |||||||||
| Total Assets | EUR mil | ... | ... | ... | |||||||||
| Trade Payables | EUR mil | ... | ... | ... | |||||||||
| Short-Term Debt | EUR mil | ... | ... | ... | |||||||||
| Other ST Liabilities | EUR mil | ... | ... | ... | |||||||||
| Current Liabilities | EUR mil | ... | ... | ... | |||||||||
| Long-Term Debt | EUR mil | ... | ... | ... | |||||||||
| Other LT Liabilities | EUR mil | ... | ... | ... | |||||||||
| Non-Current Liabilities | EUR mil | ... | ... | ... | |||||||||
| Liabilities | EUR mil | ... | ... | ... | |||||||||
| Equity Before Minority Interest | EUR mil | ... | ... | ... | |||||||||
| Minority Interest | EUR mil | ... | ... | ... | |||||||||
| Equity | EUR mil | ... | ... | ... | |||||||||
| growth rates | |||||||||||||
| Total Asset Growth | % | ... | ... | ... | ... | ||||||||
| Shareholders' Equity Growth | % | ... | ... | ... | ... | ||||||||
| Net Debt Growth | % | ... | ... | ... | ... | ||||||||
| Total Debt Growth | % | ... | ... | ... | ... | ... | ... | ||||||
| ratios | |||||||||||||
| Total Debt | EUR mil | ... | ... | ... | |||||||||
| Net Debt | EUR mil | ... | ... | ... | |||||||||
| Working Capital | EUR mil | ... | ... | ... | |||||||||
| Capital Employed | EUR mil | ... | ... | ... | |||||||||
| Net Debt/Equity | % | ... | ... | ... | |||||||||
| Current Ratio | ... | ... | ... | ||||||||||
| Quick Ratio | ... | ... | ... |
| cash flow | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
| cash flow | |||||||||||||
| Net Profit | EUR mil | ... | ... | ... | ... | ||||||||
| Depreciation | EUR mil | ... | ... | ... | ... | ||||||||
| Non-Cash Items | EUR mil | ... | ... | ... | ... | ... | |||||||
| Change in Working Capital | EUR mil | ... | ... | ... | ... | ||||||||
| Total Cash From Operations | EUR mil | ... | ... | ... | ... | ... | |||||||
| Capital Expenditures | EUR mil | ... | ... | ... | ... | ... | |||||||
| Total Cash From Investing | EUR mil | ... | ... | ... | ... | ... | |||||||
| Dividends Paid | EUR mil | ... | ... | ... | ... | ... | |||||||
| Issuance Of Shares | EUR mil | ... | ... | ... | ... | ||||||||
| Issuance Of Debt | EUR mil | ... | ... | ... | ... | ||||||||
| Total Cash From Financing | EUR mil | ... | ... | ... | ... | ... | |||||||
| Net Change In Cash | EUR mil | ... | ... | ... | ... | ||||||||
| ratios | |||||||||||||
| Days Sales Outstanding | days | ... | ... | ... | ... | ||||||||
| Days Sales Of Inventory | days | ... | ... | ... | ... | ||||||||
| Days Payable Outstanding | days | ... | ... | ... | ... | ||||||||
| Cash Conversion Cycle | days | ... | ... | ... | ... | ||||||||
| Cash Earnings | EUR mil | ... | ... | ... | ... | ||||||||
| Free Cash Flow | EUR mil | ... | ... | ... | ... | ... | |||||||
| Capital Expenditures (As % of Sales) | % | ... | ... | ... | ... | ... |
| other ratios | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
| Operating Cost (As % of Sales) | % | ... | ... | ... | ... | ||||||||
| Staff Cost (As % of Sales) | % | ... | ... | ... | ... | ||||||||
| Effective Tax Rate | % | ... | ... | ... | ... | ||||||||
| Total Revenue Growth (5-year average) | % | ... | ... | ... | ... | ... | ... | ... | ... | ... |
| valuation | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
| Market Capitalisation | USD mil | 17.7 | 16.3 | 15.3 | |||||||||
| Enterprise Value (EV) | USD mil | ... | ... | ... | |||||||||
| Number Of Shares | mil | 1.00 | 1.00 | 1.00 | |||||||||
| Share Price | EUR | 14.4 | 14.4 | 14.4 | |||||||||
| EV/EBITDA | ... | ... | ... | ... | |||||||||
| Price/Earnings (P/E) | ... | ... | ... | ... | |||||||||
| Price/Cash Earnings (P/CE) | ... | ... | ... | ... | |||||||||
| P/FCF | ... | ... | ... | ... | ... | ||||||||
| Price/Book Value (P/BV) | ... | ... | ... | ||||||||||
| Dividend Yield | % | ... | ... | ... | ... | ||||||||
| Free Cash Flow Yield | % | ... | ... | ... | ... | ... | |||||||
| Earnings Per Share (EPS) | EUR | ... | ... | ... | ... | ||||||||
| Cash Earnings Per Share | EUR | ... | ... | ... | ... | ||||||||
| Free Cash Flow Per Share | EUR | ... | ... | ... | ... | ... | |||||||
| Book Value Per Share | EUR | ... | ... | ... | |||||||||
| Dividend Per Share | EUR | ... | ... | ... | ... | ||||||||
| EV/Sales | ... | ... | ... | ... | |||||||||
| EV/EBIT | ... | ... | ... | ... | |||||||||
| EV/Free Cash Flow | ... | ... | ... | ... | ... | ||||||||
| EV/Capital Employed | ... | ... | ... | ||||||||||
| Earnings Per Share Growth | % | ... | ... | ... | ... | ... | |||||||
| Cash Earnings Per Share Growth | % | ... | ... | ... | ... | ... | |||||||
| Book Value Per Share Growth | % | ... | ... | ... | ... |
Get all company financials in excel:
By Helgi Library - July 9, 2025
EC Pharmacies made a net profit of EUR -0.755 mil in 2024, up 0% compared to the previous year. Historically, between 2024 and 2024, the company's net profit reached a high of EUR -0.755 mil in 2024 and a low of EUR -0.755 mil in 2024. The result implies ...
By Helgi Library - July 14, 2025
EC Pharmacies stock traded at EUR 14.4 per share at the end 2024 implying a market capitalization of USD 15.9 mil. Since the end of 2019, stock has appreciated by % implying an annual average growth of % In absolute terms, the value of the company rose ...
By Helgi Library - July 14, 2025
EC Pharmacies's net debt stood at EUR -0.477 mil and accounted for -12.3% of equity at the end of 2024. The ratio is up 14.1 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of -12.3% in 2024 and a low ...
By Helgi Library - July 14, 2025
EC Pharmacies stock traded at EUR 14.4 per share at the end 2024 translating into a market capitalization of USD 15.9 mil. Since the end of 2019, the stock has appreciated by 0% representing an annual average growth of %. At the end of 2024, the firm tra...
By Helgi Library - July 9, 2025
EC Pharmacies invested a total of in , down 0% compared to the previous year. Historically, between 2025 - , the company's investments stood at a high of EUR 2.96 mil in 2025 and a low of EUR 0.500 mil in 2031. As a percentage of tot...
EC Pharmacies has been growing its sales by a year on average in the last 5 years. EBITDA has grown by 0% during that time to total of in 2031, or of sales. That’s compared to % average margin seen in last five years.
The company netted in 2031 implying ROE of and ROCE of . Again, the average figures were % and %, respectively when looking at the previous 5 years.
EC Pharmacies’s net debt amounted to at the end of 2031, or of equity. When compared to EBITDA, net debt was x, up when compared to average of x seen in the last 5 years.
EC Pharmacies stock traded at per share at the end of 2031 resulting in a market capitalization of . Over the previous five years, stock price grew by 0% or % a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of x and price to earnings (PE) of x as of 2031.
Helgi Library 
